Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Wells Fargo & Co — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while Wells Fargo & Co trades at $82.02 (market cap $242.71B). The key difference: Wells Fargo & Co is far larger — about 141.9× Nuvation Bio Inc. Class A Common Stock's market cap, and Wells Fargo & Co pays a 2.49% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Wells Fargo & Co for 87 Days on average.
| NUVB | WFC | |
|---|---|---|
Market Cap | $1.71B | $242.71B |
Volume | 5,448,712 | 13,542,533 |
Sector | Health | Financials |
52-Week High | $9.54 | $96.40 |
52-Week Low | $3.41 | $73.42 |
Typical Hold Time | 0 Days | 87 Days |
Enterprise Value | $1.30B | $498.47B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wells Fargo (WFC) trades at $82.06, up 0.67% today, with a bearish technical signal despite recent earnings beat. The stock shows strong fundamentals with 25.97% net income margin and 13.13% ROE, trading at attractive valuations (P/E 11.67, P/B 1.47). Recent credit rating upgrade to 'A-' by S&P and stable Fed stress test changes provide positive catalysts, though negative operating cash flow of -$19B in 2025 raises concerns.
WFC presents a compelling value opportunity with analyst consensus target of $99.13 (21% upside), supported by improving profitability and stable regulatory environment. Key risks include volatile cash flows, rising interest rate pressures, and execution challenges in maintaining recent momentum. The balanced analyst sentiment (47% Buy, 47% Hold) suggests cautious optimism for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
